TY - JOUR A1 - Morimoto, Yoshiro A1 - Shimada-Sugimoto, Mihoko A1 - Otowa, Takeshi A1 - Yoshida, Shintaro A1 - Kinoshita, Akira A1 - Mishima, Hiroyuki A1 - Yamaguchi, Naohiro A1 - Mori, Takatoshi A1 - Imamura, Akira A1 - Ozawa, Hiroki A1 - Kurotaki, Naohiro A1 - Ziegler, Christiane A1 - Domschke, Katharina A1 - Deckert, Jürgen A1 - Umekage, Tadashi A1 - Tochigi, Mamoru A1 - Kaiya, Hisanobu A1 - Okazaki, Yuji A1 - Tokunaga, Katsushi A1 - Sasaki, Tsukasa A1 - Yoshiura, Koh-ichiro A1 - Ono, Shinji T1 - Whole-exome sequencing and gene-based rare variant association tests suggest that PLA2G4E might be a risk gene for panic disorder JF - Translational Psychiatry N2 - Panic disorder (PD) is characterized by recurrent and unexpected panic attacks, subsequent anticipatory anxiety, and phobic avoidance. Recent epidemiological and genetic studies have revealed that genetic factors contribute to the pathogenesis of PD. We performed whole-exome sequencing on one Japanese family, including multiple patients with panic disorder, which identified seven rare protein-altering variants. We then screened these genes in a Japanese PD case–control group (384 sporadic PD patients and 571 controls), resulting in the detection of three novel single nucleotide variants as potential candidates for PD (chr15: 42631993, T>C in GANC; chr15: 42342861, G>T in PLA2G4E; chr20: 3641457, G>C in GFRA4). Statistical analyses of these three genes showed that PLA2G4E yielded the lowest p value in gene-based rare variant association tests by Efficient and Parallelizable Association Container Toolbox algorithms; however, the p value did not reach the significance threshold in the Japanese. Likewise, in a German case–control study (96 sporadic PD patients and 96 controls), PLA2G4E showed the lowest p value but again did not reach the significance threshold. In conclusion, we failed to find any significant variants or genes responsible for the development of PD. Nonetheless, our results still leave open the possibility that rare protein-altering variants in PLA2G4E contribute to the risk of PD, considering the function of this gene. KW - clinical genetics KW - medical genetics Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-224192 VL - 8 ER - TY - JOUR A1 - Boelch, Sebastian P. A1 - Gurok, Anna A1 - Gilbert, Fabian A1 - Weißenberger, Manuel A1 - Rudert, Maximilian A1 - Barthel, Thomas A1 - Reppenhagen, Stephan T1 - Why compromise the patella? Five-year follow-up results of medial patellofemoral ligament reconstruction with soft tissue patellar fixation JF - International Orthopaedics N2 - Purpose This study investigates the redislocation rate and functional outcome at a minimum follow-up of five years after medial patellofemoral ligament (MPFL) reconstruction with soft tissue patellar fixation for patella instability. Methods Patients were retrospectively identified and knees were evaluated for trochlea dysplasia according to Dejour, for presence of patella alta and for presence of cartilage lesion at surgery. At a minimum follow-up of five years, information about an incident of redislocation was obtained. Kujala, Lysholm, and Tegner questionnaires as well as range of motion were used to measure functional outcome. Results Eighty-nine knees were included. Follow-up rate for redislocation was 79.8% and for functional outcome 58.4%. After a mean follow-up of 5.8 years, the redislocation rate was 5.6%. There was significant improvement of the Kujala score (68.8 to 88.2, p = 0.000) and of the Lysholm score (71.3 to 88.4, p = 0.000). Range of motion at follow-up was 149.0° (115–165). 77.5% of the knees had patella alta and 52.9% trochlear dysplasia types B, C, or D. Patellar cartilage legions were present in 54.2%. Redislocations occurred in knees with trochlear dysplasia type C in combination with patella alta. Conclusion MPFL reconstruction with soft tissue patellar fixation leads to significant improvement of knee function and low midterm redislocation rate. Patients with high-grade trochlear dysplasia should be considered for additional osseous correction. KW - MPFL KW - medial patellofemoral ligament KW - patella instability KW - patella dislocation KW - trochlear dysplasia KW - patella alta Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-235751 SN - 0341-2695 VL - 45 ER - TY - JOUR A1 - Elliot, Perry M. A1 - Germain, Dominique P. A1 - Hilz, Max J. A1 - Spada, Marco A1 - Wanner, Christoph A1 - Falissard, Bruno T1 - Why systematic literature reviews in Fabry disease should include all published evidence JF - European Journal of Medical Genetics N2 - Fabry disease is an X-linked inherited, progressive disorder of lipid metabolism resulting from the deficient activity of the enzyme α-galactosidase. Enzyme replacement therapy (ERT) with recombinant agalsidase, with intravenous infusions of either agalsidase beta or agalsidase alfa, is available and clinical experience now exceeds 15 years. There are very few randomised, placebo-controlled clinical trials evaluating the outcomes of ERT. Data are often derived from observational, registry-based studies and case reports. Pooled analysis of data from different sources may be limited by the heterogeneity of the patient populations, outcomes and treatment. Therefore, comprehensive systematic literature reviews of unpooled data are needed to determine the effects of ERT on disease outcomes. A systematic literature search was conducted in the Embase and PubMed (MEDLINE) databases to retrieve original articles that evaluated outcomes of ERT in patients with Fabry disease; the outcome data were analysed unpooled. The literature analysis included the full range of published literature including observational studies and case series/case reports. Considerable heterogeneity was found among the studies, with differences in sample size, statistical methods, ERT regimens and patient demographic and clinical characteristics. We have demonstrated the value of performing an unpooled systematic literature review of all published evidence of ERT outcomes in Fabry disease, highlighting that in a rare genetic disorder like Fabry disease, which is phenotypically diverse, different patient populations can require different disease management and therapeutic goals depending on age, genotype, and disease severity/level of organ involvement. In addition, these findings are valuable to guide the design and reporting of new clinical studies. KW - Fabry disease KW - enzyme replacement therapy KW - systematic literature review Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226654 VL - 62 ER - TY - JOUR A1 - Wyler, Emanuel A1 - Menegatti, Jennifer A1 - Franke, Vedran A1 - Kocks, Christine A1 - Boltengagen, Anastasiya A1 - Hennig, Thomas A1 - Theil, Kathrin A1 - Rutkowski, Andrzej A1 - Ferrai, Carmelo A1 - Baer, Laura A1 - Kermas, Lisa A1 - Friedel, Caroline A1 - Rajewsky, Nikolaus A1 - Akalin, Altuna A1 - Dölken, Lars A1 - Grässer, Friedrich A1 - Landthaler, Markus T1 - Widespread activation of antisense transcription of the host genome during herpes simplex virus 1 infection JF - Genome Biology N2 - Background Herpesviruses can infect a wide range of animal species. Herpes simplex virus 1 (HSV-1) is one of the eight herpesviruses that can infect humans and is prevalent worldwide. Herpesviruses have evolved multiple ways to adapt the infected cells to their needs, but knowledge about these transcriptional and post-transcriptional modifications is sparse. Results Here, we show that HSV-1 induces the expression of about 1000 antisense transcripts from the human host cell genome. A subset of these is also activated by the closely related varicella zoster virus. Antisense transcripts originate either at gene promoters or within the gene body, and they show different susceptibility to the inhibition of early and immediate early viral gene expression. Overexpression of the major viral transcription factor ICP4 is sufficient to turn on a subset of antisense transcripts. Histone marks around transcription start sites of HSV-1-induced and constitutively transcribed antisense transcripts are highly similar, indicating that the genetic loci are already poised to transcribe these novel RNAs. Furthermore, an antisense transcript overlapping with the BBC3 gene (also known as PUMA) transcriptionally silences this potent inducer of apoptosis in cis. Conclusions We show for the first time that a virus induces widespread antisense transcription of the host cell genome. We provide evidence that HSV-1 uses this to downregulate a strong inducer of apoptosis. Our findings open new perspectives on global and specific alterations of host cell transcription by viruses. KW - Virology KW - Herpes KW - Virus KW - Antisense KW - Transcription KW - IncRNA KW - ICP4 KW - BBC3 KW - NFKB Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173381 VL - 18 ER - TY - JOUR A1 - Rutkowski, Andrzej J. A1 - Erhard, Florian A1 - L'Hernault, Anne A1 - Bonfert, Thomas A1 - Schilhabel, Markus A1 - Crump, Colin A1 - Rosenstiel, Philip A1 - Efstathiou, Stacey A1 - Zimmer, Ralf A1 - Friedel, Caroline C. A1 - Dölken, Lars T1 - Widespread disruption of host transcription termination in HSV-1 infection JF - Nature Communications N2 - Herpes simplex virus 1 (HSV-1) is an important human pathogen and a paradigm for virus-induced host shut-off. Here we show that global changes in transcription and RNA processing and their impact on translation can be analysed in a single experimental setting by applying 4sU-tagging of newly transcribed RNA and ribosome profiling to lytic HSV-1 infection. Unexpectedly, we find that HSV-1 triggers the disruption of transcription termination of cellular, but not viral, genes. This results in extensive transcription for tens of thousands of nucleotides beyond poly(A) sites and into downstream genes, leading to novel intergenic splicing between exons of neighbouring cellular genes. As a consequence, hundreds of cellular genes seem to be transcriptionally induced but are not translated. In contrast to previous reports, we show that HSV-1 does not inhibit co-transcriptional splicing. Our approach thus substantially advances our understanding of HSV-1 biology and establishes HSV-1 as a model system for studying transcription termination. KW - herpes simplex virus KW - RNA polymerase II KW - gene expression KW - alpha-globin KW - motif discovery KW - regulatory protein ICP27 KW - poly(A) site usage KW - pre-messenger RNA KW - splicing inhibition KW - type 1 ICP27 Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148643 VL - 6 IS - 7126 ER - TY - THES A1 - Kalb, Stefanie T1 - Wilhelm Neumann (1898 - 1965) - Leben und Werk unter besonderer Berücksichtigung seiner Rolle in der Kampfstoff-Forschung T1 - Wilhelm Neumann (1898-1965) - His life and his work with special regard to his role in the research of chemical warfare agents N2 - Gegenstand der vorliegenden Untersuchung ist das Leben und Werk des deutschen Pharmakologen und Toxikologen Wilhelm Neumann (11. Februar 1898 - 15. April 1965). Wesentliche Erkenntnisse hierzu konnten aus Aktenbeständen des Bundesarchivs der Bundesrepublik Deutschland in Berlin-Lichterfelde, Freiburg im Breisgau, und Koblenz, des Dekanatsarchiv der Medizinischen Fakultät der Bayerischen Julius-Maximilians-Universität Würzburg, des Archivs der „Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie“ in Mainz, des Scheringianums, dem Archiv der Schering AG in Berlin, des Staatsarchivs Würzburg und des Universitätsarchivs der Bayerischen Julius-Maximilians-Universität Würzburg gewonnen werden. Von 1919 bis 1923 studierte Wilhelm Neumann in Berlin Chemie und promovierte in der chemischen Abteilung des Preußischen Instituts für Infektionskrankheiten „Robert Koch“ zum Dr. phil. Im Jahr 1924 trat er eine Stelle als Privatassistent am Pharmakologischen Institut der Universität Würzburg unter der Leitung Ferdinand Flurys an. Parallel zu seiner Arbeit am Pharmakologischen Institut studierte er von 1929 bis 1934 an der Universität Würzburg Humanmedizin und promovierte zum Dr. med. 1937 folgte seine Habilitation und die Ernennung zum Dozenten. Weitere Stationen seiner wissenschaftlichen Laufbahn am Pharmakologischen Institut waren die Ernennungen zum planmäßigen Assistenten 1939, zum Konservator 1941 und zum außerplanmäßigen Professor 1942. Im Jahr 1937 nahm Wilhelm Neumann als Arzt der Reserve seine militärische Karriere im Sanitätsdienst der Wehrmacht auf. Während des Zweiten Weltkrieges war er als „beratender Arzt“ und als Wissenschaftler für die Wehrmacht tätig. Neumanns politischer Werdegang begann im Juli 1933 mit seinem Beitritt zur Veteranenorganisation Stahlhelm. Im Februar 1934 wurde er Mitglied der SA, und ab dem 1. Mai 1937 gehörte er der NSDAP an. Nach Ende des Zweiten Weltkrieges wurde Neumann im Zuge des Entnazifizierungsprozesses 1946 aus dem Staatsdienst entlassen. Das 1947 ergangene Spruchkammerurteil reihte ihn in die Gruppe der „Mitläufer“ ein. Infolgedessen konnte er 1948 wieder von der Universität Würzburg eingestellt werden. Im Jahr 1949 wurde er dort zum ordentlichen Professor für Pharmakologie und Toxikologie berufen. Von 1954 bis 1955 übte er das Amt des Dekans der Medizinischen Fakultät der Universität Würzburg aus. Am Pharmakologischen Institut der Universität Würzburg untersuchte Neumann zunächst die Chemie und Pharmakologie der herzwirksamen Glykoside. Ihm gelang auf diesem Gebiet die Reindarstellung eines neuen Wirkstoffs, der 1935 von der Firma Schering im Herzinsuffizienztherapeutikum Folinerin auf den Markt gebracht wurde. Auf toxikologischem Gebiet arbeitete er von 1925 bis 1945 mit Ferdinand Flury an gewerbetoxikologischen Projekten und in der chemischen Kampfstoff-Forschung. Als ordentlicher Professor widmete sich Wilhelm Neumann dann neben eigenen toxikologischen Arbeiten der Förderung der Toxikologie als Fachrichtung. Zu Beginn der 1950er Jahre befasste er sich mit tierischen Giften und erforschte die Toxikologie der Reizgase und der Luftverschmutzung. Von 1955 bis 1965 war Wilhelm Neumann Vorsitzender der DFG-Kommission zur Prüfung gesundheitsschädlicher Arbeitsstoffe. N2 - The present investigation deals with the life and work of the German pharmacologist and toxicologist Wilhelm Neumann (11th February 1898 to 15th April 1965). Relevant findings to this subject were gathered from files of the ”Bundesarchiv” of the Federal Republic of Germany in Berlin-Lichterfelde, Freiburg im Breisgau and Koblenz, of the Dean’s Archives of the Faculty of Medicine of the Bavarian Julius-Maximilians-University in Würzburg, of the Archives of the “Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie” in Mainz, of the Scheringianum, the archives of Schering AG in Berlin, of the “Staatsarchiv Würzburg” and of the University Archives of the Julius- Maximilians- University Würzburg. Wilhelm Neumann studied chemistry in Berlin from 1919 to 1923 and did a doctor’s degree in the chemical department of the “Preußisches Institut für Infektionskrankheiten <>”. In 1924 he accepted a post as a private assistant at the Pharmacological Institute of Würzburg University led by Ferdinand Flury. Parallel to his work at the Pharmacological Institute Neumann studied human medicine at Würzburg University from 1929 to 1934, ending with a doctor’s degree. In 1937 he qualified as a university lecturer and then as an assistant professor. Further stages of his scientific career at the Pharmacological Institute were the appointment to regular assistant in 1939, to curator in 1941 and to associate professor in 1942. In 1937 Wilhelm Neumann had started upon his military career as a reserve doctor in the medical corps of the “Wehrmacht”. During World War II he worked as a consultant doctor and as a scientist for the “Wehrmacht”. His political career had started in July 1933 with his joining the veterans’ organization “Stahlhelm”. In February 1934 he became a member of the “SA” and from 1st May 1937 he belonged to the “NSDAP”. After World War II Neumann was dismissed as a civil servant in the course of de-Nazification. In 1947 the court ruled that he was to be ranked with “Mitläufer”. Consequently he could be re-employed by the University of Würzburg. Here he was appointed full professsor for pharmacology and toxicology in 1949. From 1954 to 1955 he held the office of the Dean of the Faculty of Medicine at Würzburg University. At the Institute of Pharmacology of Würzburg University Neumann first investigated into the chemistry and pharmacology of glycosids. In this field he succeeded in the pure preparation of a new active substance, which in 1935 was put on the market by Schering Firm as the cardiac insufficiency therapeutics “Folinerin”. It is in the field of toxicology that he had co-operated with Ferdinand Flury from 1925 to 1945, dealing with projects of occupational toxicology and with chemical research of chemical warfare agents. As a professor Wilhelm Neumann then applied himself to the promotion of toxicology as a subject area, besides his own toxicological works. At the beginning of the 1950es he dealt with animal poisons and researched into the toxicology of irritant gases and of air pollution. From 1955 to 1965 Wilhelm Neumann was the chairman of the “DFG-Kommission zur Prüfung gesundheitsschädlicher Arbeitsstoffe“. KW - Geschichte der Medizin KW - Pharmakologie KW - Toxikologie KW - history of medicine KW - pharmacology KW - toxicology Y1 - 2005 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-16124 ER - TY - JOUR A1 - Fiore, Piera Filomena A1 - Vacca, Paola A1 - Tumino, Nicola A1 - Besi, Francesca A1 - Pelosi, Andrea A1 - Munari, Enrico A1 - Marconi, Marcella A1 - Caruana, Ignazio A1 - Pistoia, Vito A1 - Moretta, Lorenzo A1 - Azzarone, Bruno T1 - Wilms' tumor primary cells display potent immunoregulatory properties on NK cells and macrophages JF - Cancers N2 - The immune response plays a crucial defensive role in cancer growth and metastasis and is a promising target in different tumors. The role of the immune system in Wilm’s Tumor (WT), a common pediatric renal malignancy, is still to be explored. The characterization of the immune environment in WT could allow the identification of new therapeutic strategies for targeting possible inhibitory mechanisms and/or lowering toxicity of the current treatments. In this study, we stabilized four WT primary cultures expressing either a blastematous (CD56\(^+\)/CD133\(^−\)) or an epithelial (CD56\(^−\)/CD133\(^+\)) phenotype and investigated their interactions with innate immune cells, namely NK cells and monocytes. We show that cytokine-activated NK cells efficiently kill WT cells. However, after co-culture with WT primary cells, NK cells displayed an impaired cytotoxic activity, decreased production of IFNγ and expression of CD107a, DNAM-1 and NKp30. Analysis of the effects of the interaction between WT cells and monocytes revealed their polarization towards alternatively activated macrophages (M2) that, in turn, further impaired NK cell functions. In conclusion, we show that both WT blastematous and epithelial components may contribute directly and indirectly to a tumor immunosuppressive microenvironment that is likely to play a role in tumor progression. KW - Wilm's tumor KW - NK cells KW - macrophages KW - tumor microenvironment KW - Wilms' tumor Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-222981 SN - 2072-6694 VL - 13 IS - 2 ER - TY - JOUR A1 - Kuai, Yue A1 - Gong, Xin A1 - Ding, Liya A1 - Li, Fang A1 - Lei, Lizhen A1 - Gong, Yuqi A1 - Liu, Qingmeng A1 - Tan, Huajiao A1 - Zhang, Xinxia A1 - Liu, Dongyu A1 - Ren, Guoping A1 - Pan, Hongyang A1 - Shi, Yaoyao A1 - Berberich-Siebelt, Friederike A1 - Ma, Zhengrong A1 - Zhou, Ren T1 - Wilms’ tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90 JF - Cell Communication and Signaling N2 - Background Wilms’ tumor 1-associating protein (WTAP) is a nuclear protein, which is ubiquitously expressed in many tissues. Furthermore, in various types of malignancies WTAP is overexpressed and plays a role as an oncogene. The function of WTAP in diffuse large B-cell lymphoma (DLBCL), however, remains unclear. Methods Immunohistochemistry was applied to evaluate the levels of WTAP expression in DLBCL tissues and normal lymphoid tissues. Overexpression and knock-down of WTAP in DLBCL cell lines, verified on mRNA and protein level served to analyze cell proliferation and apoptosis in DLBCL cell lines by flow cytometry. Finally, co-immunoprecipitation (Co-IP), IP, and GST-pull down assessed the interaction of WTAP with Heat shock protein 90 (Hsp90) and B-cell lymphoma 6 (BCL6) as well as determined the extend of its ubiquitinylation. Results WTAP protein levels were consistently upregulated in DLBCL tissues. WTAP promoted DLBCL cell proliferation and improved the ability to confront apoptosis, while knockdown of WTAP in DLBCL cell lines allowed a significant higher apoptosis rate after treatment with Etoposide, an anti-tumor drug. The stable expression of WTAP was depended on Hsp90. In line, we demonstrated that WTAP could form a complex with BCL6 via Hsp90 in vivo and in vitro. Conclusion WTAP is highly expressed in DLBCL, promoting growth and anti-apoptosis in DLBCL cell lines. WTAP is a client protein of Hsp90 and can appear in a complex with BCL6 and Hsp90 in DLBCL. Down-regulation of WTAP could improve the chemotherapeutic treatments in DLBCL. KW - WTAP KW - BCL6 KW - Hsp90 KW - complex KW - DLBCL Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-230168 VL - 16 ER - TY - THES A1 - Chatzidimitriou, Nikolaos T1 - Wird die Behandlung des kindlichen Hydrocephalus durch neue Ventilsysteme verbessert? Ein Vergleich zweier Shuntsysteme T1 - Do new shunt systems improve the treatment of pediatrich hydrocephalus. A comparison between two shunt systems N2 - Der Unishunt der Firma Codman gilt als Niederdruck-System und führt in aufrechter Körperposition zur erheblichen Überdrainage. Das Delta-System der Firma Medtronic hingegen soll durch seinen Ventilmechanismus eine Überdrainage verhindern und den Liquordruck in einem physiologischen Rahmen halten. Die vorliegende Studie untersucht die Frage, ob das Delta-System gegenüber dem Unishunt einen Vorteil hinsichtlich der Überdrainage aufweist, der sich an der revisionsfreien Funktionsdauer zeigt. Unter Berücksichtigung der Ventrikelweite prüften wir insbesondere, ob die Überdrainage und die damit verbundenen Komplikationen verringert werden können. In einer retrospektiven Fall-Sammel-Studie wurden die Patientendaten von 199 Kindern im Alter zwischen einem Tag und 10.4 Jahren ausgewertet, die im Zeitraum vom 01.01.1985 bis 01.03.2002 in der Abteilung für pädiatrische Neurochirurgie der Universitätsklinik Würzburg eine Erstimplantation eines ventrikuloperitonealen oder -atrialen Shunts mit Verwendung eines Unishunts (n= 138) oder eines Delta-Systems (n=61) erhielten. Gewertet wurden alle mechanischen oder infektiösen Komplikationen, die zu einer operativen Shuntrevision führten. Bei den mechanischen Komplikationen unterschieden wir zwischen proximaler Obstruktion, distaler Obstruktion, Migration, Diskonnektion oder Katheterriss, Ventilunterfunktion und Überdrainage. Als Überdrainage wurden operationspflichtige Subduralergüsse, eindeutige Unterdruck-beschwerden und das Slit-Ventricle-Syndrom gewertet. Asymptomatische Subdural-ergüsse und andere nicht operationspflichtige Funktionsanomalien werteten wir nicht als Komplikation. Als Shuntinfektion bezeichneten wir klinische und laborchemische Zeichen einer bakteriellen Infektion, die nach Shuntexplantation abklangen. Die durchschnittliche Funktionsdauer der Shunts wurde in vorliegender Studie durch das Delta-System nicht verlängert. Die kumulative Revisionswahrscheinlichkeit nach einem Jahr betrug beim Unishunt 30.6 %, beim Delta-System 24.9 %, lag aber nach fünf Jahren mit 58.0 % beim Delta-System höher als beim Unishunt (40.9 %). Bei den mechanischen Komplikationen ergab sich als wesentlicher Unterschied zwischen beiden getesteten Systemen eine häufigere distale Blockade des Peritonealkatheters beim Unishunt, die aber durch häufigere Ventilfehlfunktion des Delta-Systems weitgehend ausgeglichen wurde. Die niedrigste Druckstufe führte beim Delta-System signifikant häufiger zu einer proximalen Obstruktion als die höchste. Die eigenen Untersuchungsergebnisse sprechen dafür, dass Delta-Ventile tatsächlich der Neigung zur Überdrainage entgegenwirken, ohne dass sich dieser Vorteil in der Revisionsrate bemerkbar macht. Das Delta-System führt zu einer niedrigeren Überdrainagerate und weniger Überdrainage-assoziierten Erscheinungen wie Subduralergüssen. Dieser Unterschied war am ehesten morphologisch zu erfassen, jedoch im Vergleich zum Unishunt nicht signifikant. Der Unishunt war mit einer höheren Infektionsrate von 11.6 % im Vergleich zum Delta-System (3.3 %) belastet. Der Unterschied lässt sich weder mit konstruktiven Ventilmerkmalen noch mit besonderen Maßnahmen der Infektionsprophylaxe erklären. Der im Vergleich zum Unishunt höhere Preis des Delta-Systems findet keinen Niederschlag in einer niedrigeren Komplikationsrate des Systems. N2 - The Unishunt (Codman) is a low-pressure-system and tends to excessive overdrainage in the erect position. The delta-valve is supposed to prevent overdrainage and to keep CSF in his physiologic limits.This study compares the unishunt-system with the delta-system and examines if there is any advantage regarding overdrainage and if this advantage displays in the revision-free survival of an shunt. We also considered the effect of the different shunt technologies on the ventricle width. In a retrospective analysis we reviewed the medical and surgical charts of 138 children with unishunt system and 61 childeren with delta-system who were treated with a first-time shunt implantation at the department of pediatric neurosurgery,University of Würzburg between 1.1.1985 and 1.3.2002 We considered all mechanical and infectious complications that led to a operative shunt revision. We distinguished between proximal obstruction, distal obstruction, valve obstuction, migration, disconnection or fracture of the catheter and overdrainage. Overdrainage was said to be occured in the presence of symptomatic subdural effusions that needed operative revision and the Slit-ventricle-syndrom. Asymptomatic subdural effusions and other functional anomalies that could be treated consevativly were not considered as overdrainage. Shunt infection was defined as clinical and laboratory signs of a infection that ease off with shunt explantation and antibiotic treatment. Positive Gram stains or cultures were not necessary for the diagnosis of a shunt infection. Results: the overall shunt survival was not influenced by the delta-system. The overall- complication rate in the first year after implantation was 30.6 % for the unishunt and 24.9 % for the delta-valve and 40.9 % and 58 % respectively after 5 years. Overdrainage rate was 1.4 % for the unishunt-system, no shunt revision was necessary for the delta-system, the between the two systems was not signifikant. The advantage of the delta-system concerning overdrainage was seen more morphologically, the normalization or collaps of the ventricles was seen slowlier in the delta-system, the difference to the unishunt-system was not significant. The infection rate was 11.6 % for the unishunt-system and 3.3 % for the delta-system. This difference also was not significant and cannot be explained with the parameters studied. KW - Hydrocephalus KW - Unishunt KW - Delta-Valve KW - Overdrainage Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234729 N1 - Dieses Dokument wurde aus Datenschutzgründen - ohne inhaltliche Änderungen - erneut veröffentlicht. Die ursprüngliche Veröffentlichung war am: 09.07.2005 ER - TY - THES A1 - Chatzidimitriou, Nikolaos T1 - Wird die Behandlung des kindlichen Hydrocephalus durch neue Ventilsysteme verbessert? Ein Vergleich zweier Shuntsysteme T1 - Do new shunt systems improve the treatment of pediatrich hydrocephalus. A comparison between two shunt systems N2 - Der Unishunt der Firma Codman gilt als Niederdruck-System und führt in aufrechter Körperposition zur erheblichen Überdrainage. Das Delta-System der Firma Medtronic hingegen soll durch seinen Ventilmechanismus eine Überdrainage verhindern und den Liquordruck in einem physiologischen Rahmen halten. Die vorliegende Studie untersucht die Frage, ob das Delta-System gegenüber dem Unishunt einen Vorteil hinsichtlich der Überdrainage aufweist, der sich an der revisionsfreien Funktionsdauer zeigt. Unter Berücksichtigung der Ventrikelweite prüften wir insbesondere, ob die Überdrainage und die damit verbundenen Komplikationen verringert werden können. In einer retrospektiven Fall-Sammel-Studie wurden die Patientendaten von 199 Kindern im Alter zwischen einem Tag und 10.4 Jahren ausgewertet, die im Zeitraum vom 01.01.1985 bis 01.03.2002 in der Abteilung für pädiatrische Neurochirurgie der Universitätsklinik Würzburg eine Erstimplantation eines ventrikuloperitonealen oder -atrialen Shunts mit Verwendung eines Unishunts (n= 138) oder eines Delta-Systems (n=61) erhielten. Gewertet wurden alle mechanischen oder infektiösen Komplikationen, die zu einer operativen Shuntrevision führten. Bei den mechanischen Komplikationen unterschieden wir zwischen proximaler Obstruktion, distaler Obstruktion, Migration, Diskonnektion oder Katheterriss, Ventilunterfunktion und Überdrainage. Als Überdrainage wurden operationspflichtige Subduralergüsse, eindeutige Unterdruck-beschwerden und das Slit-Ventricle-Syndrom gewertet. Asymptomatische Subdural-ergüsse und andere nicht operationspflichtige Funktionsanomalien werteten wir nicht als Komplikation. Als Shuntinfektion bezeichneten wir klinische und laborchemische Zeichen einer bakteriellen Infektion, die nach Shuntexplantation abklangen. Die durchschnittliche Funktionsdauer der Shunts wurde in vorliegender Studie durch das Delta-System nicht verlängert. Die kumulative Revisionswahrscheinlichkeit nach einem Jahr betrug beim Unishunt 30.6 %, beim Delta-System 24.9 %, lag aber nach fünf Jahren mit 58.0 % beim Delta-System höher als beim Unishunt (40.9 %). Bei den mechanischen Komplikationen ergab sich als wesentlicher Unterschied zwischen beiden getesteten Systemen eine häufigere distale Blockade des Peritonealkatheters beim Unishunt, die aber durch häufigere Ventilfehlfunktion des Delta-Systems weitgehend ausgeglichen wurde. Die niedrigste Druckstufe führte beim Delta-System signifikant häufiger zu einer proximalen Obstruktion als die höchste. Die eigenen Untersuchungsergebnisse sprechen dafür, dass Delta-Ventile tatsächlich der Neigung zur Überdrainage entgegenwirken, ohne dass sich dieser Vorteil in der Revisionsrate bemerkbar macht. Das Delta-System führt zu einer niedrigeren Überdrainagerate und weniger Überdrainage-assoziierten Erscheinungen wie Subduralergüssen. Dieser Unterschied war am ehesten morphologisch zu erfassen, jedoch im Vergleich zum Unishunt nicht signifikant. Der Unishunt war mit einer höheren Infektionsrate von 11.6 % im Vergleich zum Delta-System (3.3 %) belastet. Der Unterschied lässt sich weder mit konstruktiven Ventilmerkmalen noch mit besonderen Maßnahmen der Infektionsprophylaxe erklären. Der im Vergleich zum Unishunt höhere Preis des Delta-Systems findet keinen Niederschlag in einer niedrigeren Komplikationsrate des Systems. N2 - The Unishunt (Codman) is a low-pressure-system and tends to excessive overdrainage in the erect position. The delta-valve is supposed to prevent overdrainage and to keep CSF in his physiologic limits.This study compares the unishunt-system with the delta-system and examines if there is any advantage regarding overdrainage and if this advantage displays in the revision-free survival of an shunt. We also considered the effect of the different shunt technologies on the ventricle width. In a retrospective analysis we reviewed the medical and surgical charts of 138 children with unishunt system and 61 childeren with delta-system who were treated with a first-time shunt implantation at the department of pediatric neurosurgery,University of Würzburg between 1.1.1985 and 1.3.2002 We considered all mechanical and infectious complications that led to a operative shunt revision. We distinguished between proximal obstruction, distal obstruction, valve obstuction, migration, disconnection or fracture of the catheter and overdrainage. Overdrainage was said to be occured in the presence of symptomatic subdural effusions that needed operative revision and the Slit-ventricle-syndrom. Asymptomatic subdural effusions and other functional anomalies that could be treated consevativly were not considered as overdrainage. Shunt infection was defined as clinical and laboratory signs of a infection that ease off with shunt explantation and antibiotic treatment. Positive Gram stains or cultures were not necessary for the diagnosis of a shunt infection. Results: the overall shunt survival was not influenced by the delta-system. The overall- complication rate in the first year after implantation was 30.6 % for the unishunt and 24.9 % for the delta-valve and 40.9 % and 58 % respectively after 5 years. Overdrainage rate was 1.4 % for the unishunt-system, no shunt revision was necessary for the delta-system, the between the two systems was not signifikant. The advantage of the delta-system concerning overdrainage was seen more morphologically, the normalization or collaps of the ventricles was seen slowlier in the delta-system, the difference to the unishunt-system was not significant. The infection rate was 11.6 % for the unishunt-system and 3.3 % for the delta-system. This difference also was not significant and cannot be explained with the parameters studied. KW - Hydrocephalus KW - Unishunt KW - Delta-Valve KW - Overdrainage KW - Hydrocephalus KW - Unishunt KW - Delta-Valve KW - Overdrainage Y1 - 2005 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-13140 N1 - Aus datenschutzrechtlichen Gründen wurde der Zugriff auf den Volltext zu diesem Dokument gesperrt. Eine inhaltlich identische neue Version ist erhältlich unter: https://doi.org/10.25972/OPUS-23472 ER -